Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew M Intlekofer

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Nature|June 29, 2018
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutationsAndrew M Intlekofer, Alan H Shih, Bo Wang, et al.
Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Nature|October 4, 2019
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesisAkihide Yoshimi, Kuan-Ting Lin, Daniel H Wiseman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Blood Cancer Journal|June 14, 2018
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assayAndrew M Intlekofer, Erel Joffe, Connie L Batlevi, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Blood|March 12, 2016
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical settingJie He, Omar Abdel-Wahab, Michelle K Nahas, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Nature|June 29, 2018
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutationsAndrew M Intlekofer, Alan H Shih, Bo Wang, et al.
Blood Advances|July 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell LymphomaSean E Healton, Manik Uppal, Pallavi K Galera, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Nature|October 4, 2019
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesisAkihide Yoshimi, Kuan-Ting Lin, Daniel H Wiseman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Blood Cancer Journal|June 14, 2018
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assayAndrew M Intlekofer, Erel Joffe, Connie L Batlevi, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Blood|March 12, 2016
Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical settingJie He, Omar Abdel-Wahab, Michelle K Nahas, et al.
Pageof 6